HK-listed Ascletis Pharma jumps most in 23 months on expanding production capacity

Ascletis Pharma

03/01/2022 03:04

** Shares of biological products developer Ascletis Pharma
Inc  1672.HK  jump 18.5% to HK$3.90, on track for their biggest
daily percentage gain February 2020
    ** Stock hits highest since June 10, up for a ninth straight
session; tenth biggest percentage gainer on the Hong Kong bourse
    ** Zhejiang, China-based co says annual production capacity
of its Ritonavir oral tablet for the treatment of SARS-CoV-2
infection has been expanded to 100 mln tablets and can be
further expanded based on market demand  urn:newsml:reuters.com:*:nFWN2TI02W
    ** It also announces the expansion of production of oral
direct-acting antiviral R&D pipeline, including ASC10 and ASC11,
for the treatment of SARS-CoV-2 infection 
    ** Hong Kong's healthcare index  .HSCIH  falls 3.8%
    ** The Hang Seng Composite Index  .HSCI  slips 0.2% and the
Hang Seng Index  .HSI  eases 0.3%

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))